deCODE and Affymetrix to develop DNA tests:
This article was originally published in Clinica
Executive Summary
Icelandic firm deCODE Genetics (Reykjavik) and Affymetrix are to collaborate on the development of DNA-based tests for predicting patients' response to drug treatments for common diseases. Using deCODE's population-based approach to pharmocogenomics and Affymetrix' GeneChip technology, the firms hope to develop tests that will allow for more personalised treatments for common diseases, such as high-cholesterol, depression, asthma, breast cancer, hypertension, schizophrenia and migraine. Affymetrix and deCODE, through its subsidiary Encode, will share the revenues from sales of tests developed under the collaboration.
You may also be interested in...
Behavioral Health Company Two Chairs Secures $72M In Equity And Debt Infusion
Two Chairs, which uses algorithms to match the right therapists with patients, secured $72m in investment to expand its business.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.
Fenty Cleanser Performance Claims Supported, But Influencer Videos Need Disclaimers – NAD
A National Advertising Division review of claims by LVMH-owned Fenty Skin determined makeup- and dirt-removal representations were substantiated by a study and subject questionnaire, but demo videos from paid endorsers must include disclosures about material connections in accordance with FTC guidelines.